Canadian reports have recommended that health as a human right must be Canada’s overarching global commitment and that the primacy of human rights should be prioritized over other elements of international law including international trade and investment law as it applies to access to pharmaceuticals. This paper uses a series of case reports to examine Canada’s commitment to this goal. Specifically, it examines cases where improved access has been in conflict with increased intellectual property rights.
Intellectual Property Rights First
November 25, 2013